Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Kang Nyeong | - |
dc.contributor.author | Lee, Oh Young | - |
dc.contributor.author | Choi, Myung-Gyu | - |
dc.contributor.author | Sohn, Chong Il | - |
dc.contributor.author | Huh, Kyu Chan | - |
dc.contributor.author | Park, Kyung Sik | - |
dc.contributor.author | Kwon, Joong Goo | - |
dc.contributor.author | Kim, Nayoung | - |
dc.contributor.author | Rhee, Poong-Lyul | - |
dc.contributor.author | Myung, Seung-Jae | - |
dc.contributor.author | Lee, Joon Seong | - |
dc.contributor.author | Lee, Kwang Jae | - |
dc.contributor.author | Park, Hyojin | - |
dc.contributor.author | Lee, Yong Chan | - |
dc.contributor.author | Choi, Suck Chei | - |
dc.contributor.author | Jung, Hye-Kyung | - |
dc.contributor.author | Jee, Sam Ryong | - |
dc.contributor.author | Choi, Chang Hwan | - |
dc.contributor.author | Kim, Gwang Ha | - |
dc.contributor.author | Park, Moo In | - |
dc.contributor.author | Sung, In Kyung | - |
dc.date.available | 2019-03-08T22:39:31Z | - |
dc.date.issued | 2014-01 | - |
dc.identifier.issn | 2093-0879 | - |
dc.identifier.issn | 2093-0887 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/12625 | - |
dc.description.abstract | Background/Aims Antispasmodics such as octylonium are widely used to manage irritable bowel syndrome (IBS) symptoms. However, the efficacy and safety of another antispasmodic, tiropramide, remain uncertain. We aimed to evaluate the efficacy and safety of tiropramide compared with octylonium in patients with IBS. Methods In this multicenter, randomized, non-inferiority trial, 287 patients with IBS (143 receiving tiropramide and 144 octylonium) were randomly allocated to either tiropramide 100 mg or octylonium 20 mg t.i.d (means 3 times a day) for 4 weeks. Primary endpoint was the mean change of abdominal pain from baseline assessed by visual analogue scales (VAS) score after 4 weeks of treatment. Secondary endpoints were the changes in abdominal pain from baseline at week 2 and in abdominal discomfort at weeks 2 and 4, using VAS scores, patient-reported symptom improvement including stool frequency and consistency, using symptom diaries, IBS-quality of life (IBS-QoL), and depression and anxiety, at week 4. Results The VAS scores of abdominal pain at week 4, were significantly decreased in both tiropramide and octylonium groups, but the change from baseline did not differ between the 2 groups (difference, -0.26 mm; 95% CI, -4.33-3.82; P = 0.901). Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL were also improved by both treatments, and the changes from baseline did not differ. The incidence of adverse events was similar in the 2 groups, and no severe adverse events involving either drug were observed. Conclusions Tiropramide is as effective as octylonium in managing abdominal pain in IBS, with a similar safety profile. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN SOC NEUROGASTERONTEROL & MOTILITY | - |
dc.title | Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium | - |
dc.type | Article | - |
dc.identifier.doi | 10.5056/jnm.2014.20.1.113 | - |
dc.identifier.bibliographicCitation | JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, v.20, no.1, pp 113 - 121 | - |
dc.identifier.kciid | ART001847898 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000329335900014 | - |
dc.identifier.scopusid | 2-s2.0-84891681482 | - |
dc.citation.endPage | 121 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 113 | - |
dc.citation.title | JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY | - |
dc.citation.volume | 20 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Irritable bowel syndrome | - |
dc.subject.keywordAuthor | Antispasmodic | - |
dc.subject.keywordAuthor | Octylonium | - |
dc.subject.keywordAuthor | Rome III criteria | - |
dc.subject.keywordAuthor | Tiropramide | - |
dc.subject.keywordPlus | ANTISPASMODIC AGENT TIROPRAMIDE | - |
dc.subject.keywordPlus | OTILONIUM BROMIDE | - |
dc.subject.keywordPlus | SMOOTH-MUSCLE | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | DISORDERS | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.